A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-05-04
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-21 (study day 4); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-03 (study day 17); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-25 (study day 39); relationship: Y
Grade 3 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-07-07 (study day 51); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-07-07 (study day 51); relationship: Y
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-30 (study day 74); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 79); relationship: N
Data queries
No data queries.